Logo image of CELC

CELCUITY INC (CELC) Stock Fundamental Analysis

NASDAQ:CELC - US15102K1007 - Common Stock

55.685 USD
+1.22 (+2.23%)
Last: 9/5/2025, 8:02:53 PM
56.11 USD
+0.42 (+0.76%)
After Hours: 9/5/2025, 8:02:53 PM
Fundamental Rating

1

Overall CELC gets a fundamental rating of 1 out of 10. We evaluated CELC against 542 industry peers in the Biotechnology industry. While CELC seems to be doing ok healthwise, there are quite some concerns on its profitability. CELC has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

CELC had negative earnings in the past year.
CELC had a negative operating cash flow in the past year.
CELC had negative earnings in each of the past 5 years.
CELC had a negative operating cash flow in each of the past 5 years.
CELC Yearly Net Income VS EBIT VS OCF VS FCFCELC Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

CELC has a Return On Assets of -81.00%. This is in the lower half of the industry: CELC underperforms 68.27% of its industry peers.
With a Return On Equity value of -335.12%, CELC is not doing good in the industry: 73.06% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -81%
ROE -335.12%
ROIC N/A
ROA(3y)-33.98%
ROA(5y)-41.85%
ROE(3y)-57.49%
ROE(5y)-59.3%
ROIC(3y)N/A
ROIC(5y)N/A
CELC Yearly ROA, ROE, ROICCELC Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20 -40 -60 -80

1.3 Margins

CELC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
CELC Yearly Profit, Operating, Gross MarginsCELC Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024

More info and screens

4

2. Health

2.1 Basic Checks

The number of shares outstanding for CELC has been increased compared to 1 year ago.
The number of shares outstanding for CELC has been increased compared to 5 years ago.
Compared to 1 year ago, CELC has a worse debt to assets ratio.
CELC Yearly Shares OutstandingCELC Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M
CELC Yearly Total Debt VS Total AssetsCELC Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

An Altman-Z score of 5.78 indicates that CELC is not in any danger for bankruptcy at the moment.
With a decent Altman-Z score value of 5.78, CELC is doing good in the industry, outperforming 77.12% of the companies in the same industry.
CELC has a Debt/Equity ratio of 2.24. This is a high value indicating a heavy dependency on external financing.
The Debt to Equity ratio of CELC (2.24) is worse than 80.63% of its industry peers.
Industry RankSector Rank
Debt/Equity 2.24
Debt/FCF N/A
Altman-Z 5.78
ROIC/WACCN/A
WACCN/A
CELC Yearly LT Debt VS Equity VS FCFCELC Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50M -50M 100M

2.3 Liquidity

A Current Ratio of 4.58 indicates that CELC has no problem at all paying its short term obligations.
CELC has a Current ratio (4.58) which is in line with its industry peers.
CELC has a Quick Ratio of 4.58. This indicates that CELC is financially healthy and has no problem in meeting its short term obligations.
CELC has a Quick ratio (4.58) which is in line with its industry peers.
Industry RankSector Rank
Current Ratio 4.58
Quick Ratio 4.58
CELC Yearly Current Assets VS Current LiabilitesCELC Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

1

3. Growth

3.1 Past

The earnings per share for CELC have decreased strongly by -31.39% in the last year.
EPS 1Y (TTM)-31.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.74%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to grow by 33.21% on average over the next years. This is a very strong growth
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-28.66%
EPS Next 2Y-15.67%
EPS Next 3Y19.55%
EPS Next 5Y33.21%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
CELC Yearly Revenue VS EstimatesCELC Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2026 2027 2028 2029 2030 2031 2032 500M 1B 1.5B
CELC Yearly EPS VS EstimatesCELC Yearly EPS VS EstimatesYearly EPS VS Estimates 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 5 10

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

CELC reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year CELC is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
CELC Price Earnings VS Forward Price EarningsCELC Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
CELC Per share dataCELC EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 -2 -3

4.3 Compensation for Growth

CELC's earnings are expected to grow with 19.55% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-15.67%
EPS Next 3Y19.55%

More info and screens

0

5. Dividend

5.1 Amount

CELC does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

CELCUITY INC

NASDAQ:CELC (9/5/2025, 8:02:53 PM)

After market: 56.11 +0.42 (+0.76%)

55.685

+1.22 (+2.23%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-14 2025-08-14/amc
Earnings (Next)11-12 2025-11-12/amc
Inst Owners73.52%
Inst Owner Change5.32%
Ins Owners11.93%
Ins Owner Change-3.23%
Market Cap2.36B
Analysts85.71
Price Target70.82 (27.18%)
Short Float %13.57%
Short Ratio3.28
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-6.58%
Min EPS beat(2)-15.3%
Max EPS beat(2)2.15%
EPS beat(4)1
Avg EPS beat(4)-12.09%
Min EPS beat(4)-17.61%
Max EPS beat(4)2.15%
EPS beat(8)4
Avg EPS beat(8)-4.16%
EPS beat(12)4
Avg EPS beat(12)-10.27%
EPS beat(16)4
Avg EPS beat(16)-12.45%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)139.41%
PT rev (3m)143.61%
EPS NQ rev (1m)-14.86%
EPS NQ rev (3m)-27.23%
EPS NY rev (1m)-11.36%
EPS NY rev (3m)-4.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 53.24
P/tB 53.24
EV/EBITDA N/A
EPS(TTM)-3.6
EYN/A
EPS(NY)-3.96
Fwd EYN/A
FCF(TTM)-2.84
FCFYN/A
OCF(TTM)-2.84
OCFYN/A
SpS0
BVpS1.05
TBVpS1.05
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -81%
ROE -335.12%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.98%
ROA(5y)-41.85%
ROE(3y)-57.49%
ROE(5y)-59.3%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 2.24
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 133.22%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.58
Quick Ratio 4.58
Altman-Z 5.78
F-Score3
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)112.26%
Cap/Depr(5y)77.3%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-31.39%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-67.74%
EPS Next Y-28.66%
EPS Next 2Y-15.67%
EPS Next 3Y19.55%
EPS Next 5Y33.21%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-71.69%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-41.32%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-190.86%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-191.38%
OCF growth 3YN/A
OCF growth 5YN/A